WVE Wave Life Sciences Ltd

Price (delayed)

$6.26

Market cap

$766.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.52

Enterprise value

$616.21M

Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using ...

Highlights
Wave Life Sciences's EPS has soared by 70% YoY and by 3.7% from the previous quarter
Wave Life Sciences's debt has decreased by 17% YoY and by 4.9% QoQ
The equity has soared by 173% YoY but it has contracted by 36% from the previous quarter
The company's net income has surged by 59% YoY but it fell by 7% QoQ
The quick ratio fell by 31% YoY and by 8% QoQ

Key stats

What are the main financial stats of WVE
Market
Shares outstanding
122.46M
Market cap
$766.6M
Enterprise value
$616.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
30.15
Price to sales (P/S)
7.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.46
Earnings
Revenue
$112.91M
EBIT
-$62.34M
EBITDA
-$53.4M
Free cash flow
-$139.43M
Per share
EPS
-$0.52
Free cash flow per share
-$1.08
Book value per share
$0.21
Revenue per share
$0.87
TBVPS
$1.82
Balance sheet
Total assets
$235.27M
Total liabilities
$202.01M
Debt
$30.53M
Equity
$25.39M
Working capital
$30.89M
Liquidity
Debt to equity
1.2
Current ratio
1.19
Quick ratio
1.09
Net debt/EBITDA
2.82
Margins
EBITDA margin
-47.3%
Gross margin
100%
Net margin
-54.6%
Operating margin
-63.9%
Efficiency
Return on assets
-26.3%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-89.8%
Return on sales
-55.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

WVE stock price

How has the Wave Life Sciences stock price performed over time
Intraday
1.46%
1 week
4.51%
1 month
19.24%
1 year
46.95%
YTD
23.96%
QTD
25.45%

Financial performance

How have Wave Life Sciences's revenue and profit performed over time
Revenue
$112.91M
Gross profit
$112.91M
Operating income
-$72.17M
Net income
-$61.67M
Gross margin
100%
Net margin
-54.6%
Wave Life Sciences's net margin has surged by 95% YoY but it has decreased by 7% QoQ
The operating margin has soared by 94% YoY but it has contracted by 7% from the previous quarter
The company's net income has surged by 59% YoY but it fell by 7% QoQ
The operating income has soared by 53% YoY but it has contracted by 6% from the previous quarter

Growth

What is Wave Life Sciences's growth rate over time

Valuation

What is Wave Life Sciences stock price valuation
P/E
N/A
P/B
30.15
P/S
7.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.46
Wave Life Sciences's EPS has soared by 70% YoY and by 3.7% from the previous quarter
The equity has soared by 173% YoY but it has contracted by 36% from the previous quarter
The P/S is 73% below the 5-year quarterly average of 26.0 and 4.5% below the last 4 quarters average of 7.4

Efficiency

How efficient is Wave Life Sciences business performance
Wave Life Sciences's ROS has soared by 95% YoY but it has decreased by 7% from the previous quarter
WVE's return on assets has surged by 65% year-on-year but it is down by 11% since the previous quarter

Dividends

What is WVE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for WVE.

Financial health

How did Wave Life Sciences financials performed over time
The total assets is 16% greater than the total liabilities
The total liabilities has contracted by 31% YoY and by 11% from the previous quarter
The quick ratio fell by 31% YoY and by 8% QoQ
Wave Life Sciences's debt is 20% higher than its equity
The equity has soared by 173% YoY but it has contracted by 36% from the previous quarter
Wave Life Sciences's debt to equity has increased by 48% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.